Secura Bio

Corporate Profile

Secura Bio is a pharmaceutical company committed to giving patients access to innovative therapies.

Headquartered in Las Vegas, Nevada, Secura Bio has global operations in 20 countries.


Joseph M. Limber

President & Chief Executive Officer

Mr. Limber has 40 years of experience in Life Sciences and was a co-founder of Secura. His leadership and value creation experience include President/CEO roles at Sequus (acquired by J&J), Praecis (acquired by Glaxo), Aclara Biosciences (acquired by LabCorp), Prometheus Laboratories (acquired by Nestle Health Science) and Genoptix (acquired by NeoGenomics). Mr. Limber’s management experience also includes senior roles at Ciba-Geigy (now Novartis) and Syntex (now Roche).

Mr. Limber’s track record includes building successful commercial organizations, relaunching high-value therapeutics, successful turnarounds and consistently delivering value to investors. Under his leadership, $3.0 billion of financings (private and public), product and M&A transactions were completed. Mr. Limber is a member of the Board of Directors of Secura Bio, Inc. and Xoma Corporation.

Jeffrey A. Ferrell

Board Member

Jeffrey A. Ferrell is the founder of Athyrium (2008) and currently serves as the firm’s Managing Partner. Mr. Ferrell has substantial investment experience in the life sciences sector across a wide range of asset classes and transaction structures.

Prior to forming Athyrium, Mr. Ferrell served in several capacities at Lehman Brothers, including overseeing life sciences investments for Global Trading Strategies (a principal investment group within Lehman) and as Vice President in Lehman Brothers’ Private Equity division focused on life sciences investments. Prior to joining Lehman in 2001, he was Principal at Schroder Ventures Life Sciences (SVLS) based in Boston. Investments Mr. Ferrell has been involved with include: Sequenom, Bioenvision (acquired by Genzyme), Jazz Pharmaceuticals, Orthovita (acquired by Stryker), Nektar Therapeutics, ISTA Pharmaceuticals, Lpath, Auxilium Pharmaceuticals, KaloBios, Fluidigm, and more. Mr. Ferrell graduated with an AB in Biochemical Sciences from Harvard College.

Mr. Ferrell currently serves on the board of Progenity (NASDAQ: PROG).

Mark E. Spring

Chief Financial Officer

Mr. Spring has 25 years of experience in Life Sciences and was a co-founder of Secura. His financial leadership experience includes capital raising, financial reporting and controls for private and public, domestic and multinational companies. Prior to Secura, Mr. Spring was Chief Financial Officer for Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless and Genoptix. In addition, Mr. Spring has extensive M&A experience with significant roles in transactions at Caremark, Dade Behring, Baxter, MedImmune, Prometheus and Genoptix. Prior to his CFO roles, he also held senior level financial positions at Baxter Healthcare and Price Waterhouse.

Mr. Spring earned a B.A. in Business Administration from Monmouth College. He also completed post-graduate studies at the University of Texas, Dallas and is a Certified Public Accountant (active).

Brett K.E. Lund, J.D., M.B.A.

Chief Legal Officer

Mr. Lund has 20 years of experience and was a co-founder of Secura. He is admitted to practice law in California and North Carolina and has extensive corporate, intellectual property, licensing, employment and private and public market financing experience. Prior to Secura, Mr. Lund was Chief Legal Officer at Genoptix and at Gevo, Inc. In addition, Mr. Lund has leadership, operating, and transaction experience as CEO of Agarigen, Inc. where he led the company’s sale to Intrexon, Inc. His prior experience also includes legal roles at Syngenta Biotechnology and at Ford Motor Company’s Wingcast subsidiary. Mr. Lund was a corporate attorney at the law firm of Cooley LLP.

Mr. Lund earned a J.D. from Duke University School of Law, an M.B.A. from the Fuqua School of Business, Duke University and a B.A. from the University of California, San Diego. He is a Certified Licensing Professional.

Juan Estruch

Head of Corporate Development

Dr. Estruch has over 25 years of experience in Life Sciences and was a co-founder of Secura. He has extensive experience in product assessment, corporate strategy, corporate development and served in increasingly senior management roles. Prior to Secura, Dr. Estruch served in senior positions or as head of corporate development for Ciba-Geigy, Novartis, Diversa, Prometheus and Genoptix. He has a proven track record for identifying under-exploited biopharmaceutical assets that are candidates for repositioning or relaunch.

Dr. Estruch earned a Ph.D. in Biochemistry and Molecular Biology from the University of Essen, Germany and Valencia, Spain. He also earned an MBA from the Fuqua School of Business, Duke University.

David M. Cohan, M.D.

Chief Medical Officer

Dr. Cohan has over 20 years of experience in Life Sciences. Prior to Secura, Dr. Cohan co-led the oncology program at Alkermes. Prior to Alkermes, Dr. Cohan held leadership roles at Amgen helping manage both solid tumor and hematologic oncology products. Prior to joining industry, Dr. Cohan was an Assistant Professor and Attending Surgeon in the Department of Head & Neck and Plastic & Reconstructive Surgery at Roswell Park Cancer Institute. Dr. Cohan is a Diplomate of the American Board of Surgery and a fellow of the American College of Surgeons and maintains active Board Certification in General Surgery. Dr. Cohan is an elected Member of the American Head & Neck Society (AHNS) and The Society of Surgical Oncology (SSO). He has authored numerous peer reviewed publications on melanoma, head & neck cancer, leukemia, and lymphoma.

Dr. Cohan graduated from Yale College and The Stanford University School of Medicine.

William J. Davis

Senior Vice President — Commercial Operations

Mr. Davis has 20+ years of Life Science experience. He has deep oncology biopharmaceutical sales and marketing experience and a track record for leading successful sales team deployment, managed care strategies, and GPO partnerships. Mr. Davis’ broad commercial therapeutics experience includes roles of increasing responsibility at Amgen, Johnson & Johnson and Pharmacia/Upjohn. At Amgen, Bill’s responsibilities included: U.S. & Global Marketing/Commercial Strategy Development, U.S. Commercial Lead for Aranesp, and Global Leadership & Performance Decision Sciences - a CEO initiative to coordinate efficiency of senior-level executives across the company. Mr. Davis' prior responsibilities include sales leadership and product launches across community, institution and government segments.

Mr. Davis earned a B.A. in Business Administration from California State University, San Bernadino.

Hector Tamburini

Vice President Manufacturing, Regulatory & Quality

Mr. Tamburini has over 30 years of experience in biotech and pharmaceutical technical operations, including manufacturing and packaging, outsourcing and regulatory filings. Prior to joining Secura Bio, he held various senior level roles at Prometheus Laboratories, Spectrum Pharmaceuticals, Biogen and Roche. During his career in the industry, Hector has been actively involved in the launch, manufacturing and supply chain of multiple drugs: small molecules and biologics, solid dosage forms as well as injectables. The wide arrange of products included domestic and international clinical and commercial distribution, in some cases acting as subject matter expert during regulatory agencies inspections.

Mr. Tamburini earned his Biochemistry degree specialized in clinical analysis from the Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. He also completed studies in Pharmacy.

Erik Bokmans

Vice President & General Manager — Europe

Erik has 28 years of international experience in the Biopharma industry, the majority in the areas of hematology and oncology. His extensive commercial and leadership experience was built on sales and marketing roles at Glaxo Wellcome, Roche and Amgen, and more recently with Celgene, where he progressed through a variety of senior and general management roles in the UK, Benelux and the Central Eastern European Region plus multiple strategic European roles. Joining at the start of Celgene’s European lifecycle, he was instrumental in its growth and commercial success, establishing new teams and commercial operations and successfully launching and negotiating national government reimbursement for over 20 new products and indications across multiple geographies.

Mr. Bokmans earned a BSc. Hons in Pharmacology at Kings College, University of London. He also completed post-graduate business studies at the London School of Economics.

Gregory S. Wessels

Vice President, Global Marketing

Mr. Wessels has over 20 years of life sciences experience in sales, marketing and commercialization strategy, most recently having served as Senior Vice President and Chief Commercial Officer of Aprea Therapeutics. Mr. Wessels also held global and regional hematology/oncology positions of increasing responsibility over more than 10 years at Celgene Corporation, culminating as Executive Director, Lymphoma Global Marketing. Prior to joining Celgene he spent 11 years with Sanofi US in sales, marketing and business planning roles.

Mr. Wessels received a BS in Biochemistry from the University of Notre Dame and an MBA from the Kellogg School of Management at Northwestern University.

Investor Contact

Mark Spring

Phone: (702) 465-41634